The House Energy and Commerce Health Subcommittee today held a hearing on implementation of the Compounding Quality Act, which updated federal requirements for drug compounding facilities after a 2012 fungal meningitis outbreak that was associated with a contaminated compounded steroid medication distributed to patients and providers in 23 states. Witnesses at the hearing included Food and Drug Administration Commissioner Scott Gottlieb, M.D.; officials from two companies that manufacture compounded sterile drugs; a patient; and representatives from the American Academy of Dermatology, International Academy of Compounding Pharmacists, The Pew Charitable Trusts, National Community Pharmacists Association, and American Academy of Ophthalmology. As FDA continues to implement the law, Gottlieb said the agency “plans to take steps that preserve lawful pharmacy practices and expand the opportunities for pharmacies that want to engage in larger-scale compounding to efficiently become 503B facilities.”

Related News Articles

Headline
In a letter today to leaders of the Senate Health, Education, Labor and Pensions Committee, the AHA and five other national hospital groups said they agree…
Headline
Senate Health, Education, Labor and Pensions Committee leaders today released a manager’s amendment to the Lower Health Care Costs Act of 2019 (S.1895) –…
Headline
The AHA today submitted comments on the revised version of the Lower Health Care Costs Act (S. 1895), legislation to prevent surprise medical bills, reduce…
Headline
The House Ways and Means Committee today passed the Economic Mobility Act (H.R. 3300), tax legislation that includes an AHA-supported provision to repeal a…
Headline
The House of Representatives yesterday voted 226-203 to approve a package of four appropriations bills for fiscal year 2020, which includes legislation that…
Headline
Sens. Lamar Alexander, R-Tenn., and Patty Murray, D-Wash., today introduced the Lower Health Care Costs Act (S.1895), legislation to prevent surprise medical…